A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

NCT03558152 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

195

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: UTTR1147A
DRUG: UTTR1147A Placebo
DRUG: Vedolizumab
DRUG: Vedolizumab Placebo

Sponsor

Genentech, Inc.